Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain ... on third parties to develop biologic treatments as it does not have the expertise in-house.

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... the most common form of eczema, around 1.5 million adults in the UK alone have the condition. Sanofi’s UK affiliate ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

In moderate to severe cases of eczema when topical prescription treatments have not worked well or aren't advised, biologics such as Dupixent (dupilumab) and Adbry (tralokinumab-ldrm), or Janus kinase ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...